New Roche Award for Antibody-based Cancer Therapy Research
PENZBERG, Germany, May 15, 2013 /PRNewswire/ --
Researchers from academia throughout Europe are invited to participate
In a newly created award, pRED`s Discovery Oncology unit of Roche (SIX: RO, ROG; OTCQX: RHHBY) in Penzberg, Germany invites European researchers to submit abstracts which describe their scientific work in the field of tumor-selective membrane targets for antibody-based cancer therapy. The award aims to honor and support outstanding research in the academia field and will further strengthen Roche´s interaction with the international research community.
"Roche has a long tradition of successful exchange with many research institutions all over the world," states Klaus Bosslet, Head of Discovery Oncology Penzberg. "With the new award we emphasize our commitment to intensifying collaboration with academia and continuing support of innovative cancer research."
The abstracts will be reviewed by a jury consisting of scientific experts from academia and Roche. Qualified applicants include graduate students and postdoctoral fellows from the research labs based in Europe. The authors of the ten best contributions will be invited to the Roche Penzberg campus near Munich, for oral presentation, poster discussion and award ceremony in November 2013. The three winners will be selected at the symposium and receive an award of 4,000 €, 2,000 €, and 1,000 €, respectively.
For submission and related information, please visit http://www.roche.de/abstract. The deadline for abstract submission is August 15, 2013.
About Roche pRED
Roche's Pharma Research and Early Development organization - Roche pRED - consists of some 2,500 scientists and clinicians with a shared vision of excellence in science, a proud heritage of healthcare innovation and a commitment to deliver new and effective medicines to patients. Working in partnership with Roche's world-leading Diagnostics Division, Roche pRED strives to make personalized healthcare a reality, and change the practice of medicine for future generations. Roche pRED focuses on four therapeutic areas: oncology, neuroscience, virology and cardiovascular-metabolism at six strategic sites worldwide. For more information: http://www.roche.com
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For further information please contact:
Roche Diagnostics GmbH
Dr. Burkhard Ziebolz
Roche Diagnostics GmbH
Dr. Johannes Ritter
Head of Communication Penzberg
SOURCE Roche Diagnostics GmbH